Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Zeltia Articles

The solution for Spanish pharma companies lies abroad

13 March 2013

Spain's Zeltia is turning a corner, say Edison analysts

28 February 2013

Zeltia's Yondelis approved for sale in 10 new countries

4 December 2012

Johnson & Johnson unit voluntarily withdraws NDA for trabectedin

3 May 2011

UK NICE gives final yes for Amgen’s Nplate but no for PharmaMar’s Yondelis

27 April 2011

UK’s NICE turns down Zeltia’s Yondelis on lack of evidence for ovarian cancer drug

14 March 2011

Spain’s Zeltia posts 74% rise in EBITDA, with Yondelis sales up 65% in 2010

28 February 2011

UK’s NICE turns down PharmaMar’s Yondelis and GlaxoSmithKline’s Arzerra

20 September 2010

US FDA briefs: fast-track for Zeltia’s Zentylor; OK for Baxter’s Protopam; warning on gadolinium-based contrast agents

13 September 2010

Showing 1-9 of 9 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Australia's pharma industry applauds R&D regulatory reform
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Australia's pharma industry applauds R&D regulatory reform

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS